Deep Dive: Oncology and ASCO 2019
Deep Dive/ Oncology/ Views & Analysis
Smarter thinking about pharmaceutical marketing
mike.hammerton@pharmaphorum.com
Deep Dive: Oncology and ASCO 2019, marketing, Multichannel, patient, Robb DeFilippis, Tag
0 Comment
Deep Dive/ Oncology/ Views & Analysis/ Views and analysis
Getting patients round the virtual table
mike.hammerton@pharmaphorum.com
Deep Dive: Oncology and ASCO 2019, engagement, impetus, patient-centric
0 Comment
Deep Dive/ Oncology/ Views & Analysis/ Views and analysis
Revealing the true value of new cancer drugs to payers
mike.hammerton@pharmaphorum.com
Ben van Hout, CAR T, Deep Dive: Oncology and ASCO 2019, Marc Botteman, pharmerit international
0 Comment
Deep Dive/ Oncology/ Views & Analysis/ Views and analysis
Adapting for the future of oncology trials
mike.hammerton@pharmaphorum.com
Cytel, Deep Dive: Oncology and ASCO 2019, Oncology, R&D
0 Comment
Deep Dive/ Oncology/ Views & Analysis/ Views and analysis
Moving from autologous to allogeneic ACT paradigms
mike.hammerton@pharmaphorum.com
ACT, Acute Lymphocytic Leukaemia, Adoptive Cellular Transfer, CAR T, Deep Dive: Oncology and ASCO 2019, Gilead, ICON, Novartis
0 Comment
Deep Dive/ Oncology/ Views & Analysis
Did cancer clinical trials stay on track at ASCO 2019?
mike.hammerton@pharmaphorum.com
asco, cancer, Deep Dive: Oncology and ASCO 2019, kantar
0 Comment
Deep Dive/ Oncology/ Views & Analysis/ Views and analysis
Why pharma needs honest patient dialogue
mike.hammerton@pharmaphorum.com
Astellas, Deep Dive: Oncology and ASCO 2019, Dr Paul Tunnah, Percival Barretto-Ko
0 Comment